Helomics® Corporation and SCOPE International USA, Inc. Announce the Completion of a Strategic Agree
Helomics-SCOPE USA partnership provides pharmaceutical and diagnostic companies with a single partner capable of providing a complete range of pre-clinical and clinical trial services.
PITTSBURGH– March 23, 2017 - Helomics® Corporation (Helomics), a privately-held, healthcare company providing personalized medicine solutions for clients in the pharmaceutical, diagnostic, and biotechnology industries, and SCOPE International USA, Inc. (SCOPE USA), the North American office of an independent, full-service, contract research organization offering a complete range of clinical development services to the pharmaceutical, biotechnology, and medical device industries, today announced the completion of a strategic agreement to co-market products and services. Under the terms of the agreement, Helomics and SCOPE USA will collaborate to identify, develop, and facilitate new business opportunities with potential partners in the pharmaceutical, biotechnology, clinical diagnostics, medical device, and clinical research industries.
Alethea Wieland, President and Managing Director of North American Operations for SCOPE USA said, “We are very pleased to be partnering with Helomics, a recognized leader in oncology for personalized medicine diagnostic assay development and commercialization. This critical partnership with Helomics will augment and complement our U. S. and international business services in the ever-increasing complex fields of oncology and personalized medicine.”
“We are looking forward to collaborating with SCOPE USA in identifying new business initiatives that will benefit both organizations,” stated Gerald J. Vardzel Jr., President and CEO of Helomics. “SCOPE’s global presence combined with our strong clinical diagnostics presence in North America will yield synergistic commercial opportunities for us and value for our clients.”
Donald L. Very, Jr., PhD, Vice President of Research and Commercial Development at Helomics commented, “SCOPE International is a leading provider of comprehensive clinical trial design and management services. Their expertise, products, and services are a unique complement to ours and together, we can provide a comprehensive set of preclinical and clinical trial services to our partner-clients in the pharmaceutical, diagnostic, and medical device industries.”
About Helomics® Corporation
Helomics® is an integrated clinical contract research organization whose mission is to improve patient care by partnering with pharmaceutical, diagnostic, and academic organizations to bring innovative clinical products and technologies to the marketplace. Helomics offers advanced clinical laboratory diagnostic tests as well as scientific and non-scientific product enhancement services to provide a customized solution to our client’s specific product development needs.
Helomics® is headquartered in Pittsburgh, Pennsylvania where the company maintains state-of-the-art, CLIA-certified, clinical and research laboratories. For more information please visit: www.helomics.com.
About SCOPE International USA, Inc.
SCOPE International USA, Inc., located in Pittsburgh, Pennsylvania, is the North American office of a privately held, independent, full-service contract research organization offering a complete range of clinical development and consulting services to the pharmaceutical, biotechnology, and medical device industries. With 17 offices in Western and Eastern Europe, United Kingdom, Ukraine, Russia, and the United States, SCOPE’s dedicated staff cover more than 30 countries. For more information please visit: www.scope-international.com.
Safe Harbor Statement
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A Of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words “believes”, “expects”, “anticipates” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements.
For more information regarding Helomics Corporation, please contact:
Michelle Murgia, Marketing Communications and Design
For more information regarding SCOPE International USA, Inc., please contact:
Alethea Wieland, President and Managing Director (North American Operations)
SCOPE International USA, Inc.
Sources: Helomics® Corporation and SCOPE International USA, Inc.